Madrigal Pharmaceuticals (MDGL) Receiving Somewhat Favorable News Coverage, Study Finds

News articles about Madrigal Pharmaceuticals (NASDAQ:MDGL) have been trending somewhat positive on Monday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.6002051313395 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Madrigal Pharmaceuticals (NASDAQ MDGL) traded down $0.64 during mid-day trading on Monday, reaching $44.08. 85,600 shares of the company’s stock were exchanged, compared to its average volume of 41,822. Madrigal Pharmaceuticals has a 12 month low of $13.09 and a 12 month high of $52.35.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.11. equities research analysts expect that Madrigal Pharmaceuticals will post -2.85 earnings per share for the current year.

A number of research analysts recently weighed in on MDGL shares. Evercore ISI started coverage on shares of Madrigal Pharmaceuticals in a research note on Friday, September 22nd. They issued an “outperform” rating and a $65.00 price target on the stock. Roth Capital started coverage on shares of Madrigal Pharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $62.00 price target on the stock. Finally, JMP Securities raised their price target on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the company an “outperform” rating in a research note on Friday, October 13th.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/13/madrigal-pharmaceuticals-mdgl-receiving-somewhat-favorable-news-coverage-study-finds.html.

In other news, Director Richard S. Levy purchased 2,000 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The stock was acquired at an average price of $16.12 per share, for a total transaction of $32,240.00. Following the acquisition, the director now directly owns 7,200 shares of the company’s stock, valued at $116,064. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard S. Levy purchased 3,550 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average price of $16.12 per share, with a total value of $57,226.00. Following the acquisition, the director now directly owns 3,640 shares in the company, valued at $58,676.80. The disclosure for this purchase can be found here. Insiders have bought a total of 9,100 shares of company stock valued at $145,840 in the last 90 days. Insiders own 66.40% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Insider Buying and Selling by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply